|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | AGNP精神科治疗药物监测共识指南:2011显示文摘治疗药物监测(Therapeutic drug monitoring,TDM),如通过定量测定血清或血浆药物浓度指导用药剂量优化,已经成为对患者进行精神药物治疗的很有价值的工具。在患者用药依从性难以判断、药物耐受性不佳、治疗剂量下无效以及可能存在药代动力学药物-药物相互作用等情况下,测定药物浓度是很有用的。在精神科,有可能明显获益于TDM的主要患者群体包括儿童、孕妇、老年患者、智力障碍患者、涉及司法的患者、已知或怀疑携带药代动力学相关基因变异的患者,以及合并躯体疾病影响药代动力学的患者。然而,只有将TDM充分整合到临床治疗过程中去,才能发挥其优化药物治疗的潜在优势。为了促进TDM的合理应用,神经精神药理学与药物精神病学协会(Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie,AGNP)的TDM专家组在2004年发表了精神药物治疗药物监测指南。之后,随着知识不断更新,又有许多可能需要进行TDM的新药上市。因此,本次更新将神经精神药物的种类扩展到了128种,并将其TDM必要性划分为从'强烈推荐'到'可能有用'的四个等级。经过大量细致且全面的文献检索与分门别类的汇总整理,将基于循证医学理念的'治疗参考浓度范围'和'剂量相关参考浓度范围'呈现给大家。本共识指南引入了'实验室警戒浓度'的新概念,即实验室需要马上告知治疗医生的药物浓度上限。本共识指南还给出了诸如药物作为细胞色素P450酶的底物和抑制剂的性质,代谢物与母药浓度比值的常见范围,以及与结果解释相关的内容,还提供了何时将TDM与遗传药理学检测相结合的建议。遵循本指南,有助于改善许多患者精神药物治疗的效果,特别是那些存在药代动力学异常的患者。TDM是一门交叉学科,有时针对看起来不一致的数据,需要多学科坦诚地讨论,只有这样,患者才能从这种合作中获益。 | Hiemke C Baumann P Bergemann N Conca A Dietmaier O Egberts K Fric M Gerlach M Greiner C Gründer G Haen E Havemann-Reinecke U Jaquenoud Sirot E Kirchherr H Laux G Lutz UC Messer T Müller MJ Pfuhlmann B Rambeck B Riederer P Schoppek B Stingl J Uhr M Ulrich S Waschgler R Zernig G 李文标(译) 果伟(译) 阮灿军(译) 贺静(译) 汤宜朗(审校) 王传跃(审校) | 2016 | 实用药物与临床2016，19，10： | 37 |
| 2 | Topology impacts TRAIL therapy: Differences in primary cancer growth and liver metastasis between orthotopic and subcutaneous xenotransplants of pancreatic ductal adenocarcinoma cells显示文摘Background: To study novel treatment modalities for pancreatic ductal adenocarcinoma(PDAC), we need to transfer the knowledge from in vitro to in vivo. It is important to mirror the clinical characteristics of the typically local invasive growth of pancreatic cancer and the distant spread resulting in liver metastasis. Notably, for xenotransplant studies using human specimen, two models, i.e. subcutaneous(s.c.) and orthotopic(o.t.) transplantation are widely used. Methods: The subcutaneously and orthotopically inoculated Colo357 Bcl-x L cell-derived tumors were directly compared with and without TNF-related apoptosis inducing ligand(TRAIL) treatment. The size of primary tumors, number of liver metastasis and the histologic markers Ki67, M30, TNF-α and CD31 were assessed. Results: Upon TRAIL treatment, the primary tumors did not change their size, neither in the s.c. nor in the o.t. approaches. But when s.c. was compared to o.t., the size of the s.c. tumors was more than twofold bigger than that of the o.t. tumors( P<0.01). However, mice with orthotopically inoculated PDAC cells developed liver metastasis upon TRAIL treatment much more frequently( n=13/17) than mice with subcutaneously inoculated PDAC cells( n=1/11)( P<0.01). As a likely driving force for this increased metastasis, a higher TNF-α staining intensity in the o.t. tumors was observed by immunohistochemistry. Conclusions: These data from a direct side-by-side comparison underline the importance of the proper inoculation site of the PDAC cells. Local invasion and liver metastases are a hallmark of PDAC in the clinic;the o.t. model is clearly superior in reflecting this setting. Moreover, a serious side-effect of a possible new therapeutic compound became obvious only in the o.t. model. | Bastian Kettler Anna Trauzold Christian Röder Jan-Hendrik Egberts Holger Kalthoff | 2021 | Hepatobiliary & Pancreatic Diseases International2021，20，3： | 3 |
| 3 | Fondaparinux预防老年急性内科患者发生静脉血栓形成的效果与安全性:随机安慰剂对照研究显示文摘目的:观察 Fondaparinux 对具有中高度静脉血栓发生危险的老年急性内科住院患者的抗凝效果与安全性。设计:双盲随机安慰剂对照研究。背景:8个国家的35个中心。参与者:849例≥60岁内科患者,住院原因分别为充血性心力衰竭、慢性肺病合并急性呼吸系统疾患、急性炎症性或感染性疾病,预期至少住院4天以上。干预:2.5 mg Fondaparinux 或安慰剂,每天1次皮下注射,持续6~14天。观察指标:主要指标为静脉血栓形成(治疗后15天内采用双侧静脉造影检查)及有症状的静脉血栓;次要指标为死亡与出血。患者随访时间为1个月。结果:Fondaparinux 治疗组425例患者和安慰剂组414例患者接受了安全性分析(10例未治疗)。644例患者(75.9%)可接受主要指标分析。静脉血栓检出率在 Fondaparinux 治疗组为5.6%(18/321),安慰剂组为10.5%(34/323),相对危险减少46.7%(95% CI 7.7%~69.3%)。安慰剂组5例患者发生有症状的静脉血栓,Fondaparinux治疗组无患者发生有症状的静脉血栓(P=0.029)。两组均有1例(0.2%)患者发生严重出血。随访结束时,安慰剂组、Fondaparinux 治疗组分别死亡25(6.0%)、14(3.3%)例患者。结论:Fondaparinux 可有效预防急性内科老年患者无症状性及有症状的静脉血栓。严重出血几率两组相似。 | Alexander T Cohen Bruce L Davidson Alexander S Gallus Michael R Lassen Martin H Prins Witold Tomkowski Alexander G G Turpie Jan F M Egberts Anthonie W A Lensing 石汉平(译) 王深明(校) | 2006 | 英国医学杂志中文版2006，9，5： | 3 |
| 4 | Characterization of major histocompatibility complex class Ⅱ A and B genes in gynogenetic carp clone显示文摘 | Van Erp S H M Egberts E Stet R | 1996 | Immunogenetics1996，44，3： | 1 |
| 5 | Stability of Lefort I osteotoing with maxillary oclancement: a comparision or canbind wire fixation 显示文摘 | Egbert Hepworth B Myall R | 1995 | J Oral Maxillofac Surg1995，53，3： | 1 |
| 6 | Numerical modeling of the global semidiurnal tide in the present day and in the last glacial maximum显示文摘 | EGBERT G D RAY R D BILLS B G | 2004 | Journal of Geophysical Research2004，109，03： | 1 |
| 7 | Fine-tuning gene networks using simple sequence repeats显示文摘 | EGBERT R G KLAVINS E | 2012 | Proceedings of the National Academy of Sciences2012，109，16： | 1 |
| 8 | Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal antiinflammatory drugs显示文摘 | van Puijenbroek E P Egberts A C Heerdink E R | 2000 | European Journal of Clinical Pharmacology2000，56，： | 1 |
| 9 | Significant dissipation of tid- al energy in the deep ocean inferred from satellite altime- ter data 显示文摘 | EGBERT G D RAY R D | 2000 | Nature2000，405，15： | 1 |
| 10 | Signal selection and lbllow-up in pharmacovigilance 显示文摘 | Meyboom R H Lindquist M Egberts A C | 2002 | Drug Saf2002，25，6： | 1 |
| 11 | Significant Dissipation of Tidal Energy in the Deep Ocean Inferred from Satellite Altimeter Data显示文摘 | Egbert G D Ray R D | 2000 | Nature2000，405，6788： | 1 |
| 12 | Mortality,severe respiratory distress syndrome and chronic lung disease of the newborn are reduced more after prophylactic than therapeutic administration of the surfactant Curosurf显示文摘 | Egberts J Brand R Walti H | 1997 | Pediatr1997，，： | 1 |
| 13 | Autoantibodies directed to novel components of the PM/Scl complex,the human exosome显示文摘 | Brouwer R Egberts WV Hengstman GJD | 2002 | Arthritis Res2002，4，： | 1 |
| 14 | Causal or casual? The role of causality assessment in pharmacovigilance显示文摘 | Hekster Y A Egberts A C G | 1997 | Drug Safety1997，16，： | 1 |
| 15 | Principles of signal detection in pharmacovigilance显示文摘 | Egberts A C G Edwards I R | 1997 | Drug Safety1997，16，： | 1 |
| 16 | Significant dissipation of tidal energy in the deep ocean inferred from satellite altimeter data 显示文摘 | Egbert G D Ray R D | 2000 | Nature2000，405，6788： | 1 |
| 17 | An investigation of power line de-icing by electro-impulse methods显示文摘 | EGBERT R I SCHRAG R L BERNHART W D | 1989 | IEEE Transactions on Power Delivery1989，4，3： | 1 |
| 18 | Significant dissipation of tidal energy in the deep ocean inferred from satellite altimeter data显示文摘 | Egbert G D Ray R D | 2000 | Nature2000，405，15： | 1 |
| 19 | A simple conjunctival biop- sy显示文摘 | Egbert P R Lauber S Maurice D M | 1977 | Am J Ophthalmol1977，84，6： | 1 |
| 20 | 2-degree-of-freedom Analysis of Power-line Galloping by Describing Function Methods 显示文摘 | Byun G S Egbert R I | 1991 | Electric Power Systems Research1991，21，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员